Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Peer reviewedOpen accessGastroenteritis

Impact and effectiveness of pentavalent rotavirus vaccine in children <5 years of age in Burkina Faso

Vaccine·

Isidore Juste O. Bonkoungou, Negar Aliabadi, Eyal Leshem, Madibèlè Kam, Désiré Nezien, Maxime K. Drabo, Moumouni Nikiema, Boureima Ouedraogo, Isaïe Medah, Souleymane Konaté, Rasmata Ouédraogo-Traoré, Lassana Sangaré, Ludovic Kam, Diarra Yé, Ma Ouattara, Joseph N. Biey, Jason M. Mwenda, Jacqueline E. Tate, Umesh D. Parashar

DOI
10.1016/j.vaccine.2017.12.056
PMID
29290478
PMCID
PMC9237810
OpenAlex
W2778462376
Study type
Journal article
Publisher
Elsevier BV
Article type
journal-article
Integrity
current

Why this research matters now

The findings document the real-world impact of rotavirus vaccine in one of the first African countries to introduce RV5 nationally, demonstrating reductions in rotavirus-associated hospitalizations and supporting vaccine policy in similar settings.

01

Structured evidence summary

Research question

The study assessed the impact and effectiveness of pentavalent rotavirus vaccine (RV5) on acute gastroenteritis hospitalizations among children under five years of age in Burkina Faso following vaccine introduction in October 2013.

Study design

Sentinel hospital-based surveillance was conducted at four hospitals from December 2013 through February 2017. Unconditional logistic regression compared vaccination odds among rotavirus-positive cases and rotavirus-negative controls, adjusting for age, season, hospital site, and socioeconomic factors.

Population and setting

The study included children under five years of age hospitalized for acute gastroenteritis at four sentinel hospitals in Burkina Faso. Demographic, clinical, and vaccination data were collected, and stool specimens were tested by enzyme immunoassay.

Main findings

The proportion of acute gastroenteritis hospitalizations testing positive for rotavirus declined significantly among children under five, particularly among infants. RV5 provided significant protection against severe rotavirus gastroenteritis in infants, though effectiveness decreased in older children.

Public-health relevance

The findings document the real-world impact of rotavirus vaccine in one of the first African countries to introduce RV5 nationally, demonstrating reductions in rotavirus-associated hospitalizations and supporting vaccine policy in similar settings.

Important limitations

This summary relies on the supplied single-article abstract and bibliographic metadata. Full interpretation of study limitations, including potential selection bias from sentinel surveillance, confounding, and generalizability, requires review of the complete published article.

GIDS interpretation

The article was classified under gastroenteritis surveillance and vaccine effectiveness topics in Burkina Faso. This classification supports literature discoverability for rotavirus vaccine program evaluation but does not constitute detection of a live public health signal or outbreak event.

02

Related GIDS surveillance

Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.

03

Evidence relationships

This article has 11 auditable classifier relationships to diseases, places, topics, and study design.

about diseaseaddresses topicaddresses topicaddresses topicevaluates interventionhas pathogen typestudied instudied population settingstudies populationstudies populationuses study design